Case Study: FiercePharma achieves stronger post-approval evidence and improved provider data quality with LexisNexis Risk Solutions

How Data and Informatics are Reshaping Post-Approval for Pharmaceuticals

Enclarity, a LexisNexis company, addresses a growing industry problem: as payers demand real-world evidence and value-based reimbursement, pharmaceutical companies must prove a drug’s effectiveness in the health system while also grappling with poor provider data. Up to 25–30% of provider records change annually and common issues—duplicates, missing identifiers and wrong contact details—undermine compliance, claims processing, sales targeting and market-access efforts.

Enclarity offers a continuously updated, high-quality medical provider database and related services that improve claims processing, provider directories, regulatory reporting, marketing and sales operations. Trusted by major health plans, pharma firms and device manufacturers, its data reduces returned correspondence and data errors, sharpens targeting for post-approval evidence-generation and helps companies better engage payers and providers.

FiercePharma